Specific Considerations Peptides Containing Cysteine, Methionine, or Tryptophan Peptides with these amino acids are prone to oxidation
(2000), Horm Res 53(Suppl 3), PubMed 10971106 Statistics from preclinical literature AOD-9604 = modified fragment of hGH 177191 + N-terminal Tyr (sequence Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe), molecular weight 1815.1 Da Developed at Metabolic Pharmaceuticals (Australia) based on the work of professor Frank Ng (Monash University) in the 1990s Standard experimental dose in obesity clinical trials: 1 mg/day subcutaneously (Phase 2b, Heffernan et al.) Mechanism: stimulation of 3-adrenergic receptors in adipose tissue, increased lipolysis and fatty acid oxidation without activation of the hGH receptor (no IGF-1 increase) Phase 2b clinical trial (2007, 300 patients): weight reduction ~2.8 kg vs placebo over 12 weeks FDA status: NDI rejection (2014) as a dietary supplement
Common Side Effects (Mild and Transient) Most individuals tolerate 5-amino-1MQ well, with side effects typically mild and self-limiting
The molecular weight of 159.21 g/mol puts it in the optimal range for cellular uptake studies
The Recommended Dietary Allowance (RDA) for vitamin B12 during pregnancy is 2.6 micrograms (mcg) per day
Had no side effects